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Effective design of combination therapies requires
understanding the changes in cell physiology that
result from drug interactions. Here, we show that
the genome-wide transcriptional response to combi-
nations of two drugs, measured at a rigorously
controlled growth rate, can predict higher-order
antagonism with a third drug in Saccharomyces cer-
evisiae. Using isogrowth profiling, over 90% of the
variation in cellular response can be decomposed
into three principal components (PCs) that have clear
biological interpretations. We demonstrate that the
third PC captures emergent transcriptional programs
that are dependent on both drugs and can predict
antagonism with a third drug targeting the emergent
pathway. We further show that emergent gene
expression patterns are most pronounced at a drug
ratio where the drug interaction is strongest,
providing a guideline for future measurements. Our
results provide a readily applicable recipe for uncov-
ering emergent responses in other systems and for
higher-order drug combinations. A record of this
paper’s transparent peer review process is included
in the Supplemental Information.
INTRODUCTION
Combinatorial drug treatment is an increasingly important strat-
egy for combatingmicrobial infections and a powerful tool for un-
derstanding the molecular biology of the perturbed cell (Chen
and Lahav, 2016; Fischbach, 2011; Pemovska et al., 2018).
When two or more drugs are combined, synergistic or antago-
nistic interactions can occur. These interactions, respectively,
correspond to increased or decreased inhibitory effect of the
drug combination compared to the null expectation of additivity
(Figure 1A; Bollenbach, 2015; Loewe, 1928). In recent years,
high-throughput techniques for identifying drug interactions
(Brochado et al., 2018; Cokol et al., 2011, 2014) and their modi-
fiers (Chevereau and Bollenbach, 2015) have considerablyCell Systems 10, 1–11, J
This is an open access article undadvanced our understanding of drug interactions. Further,
frameworks for quantifying higher-order drug interactions have
been developed (Cokol et al., 2017; Russ and Kishony, 2018; Te-
kin et al., 2016). However, to rationally design combination ther-
apies, a deeper understanding of the combinatorial effects of
drugs on cell physiology and of the general principles guiding
the cellular response to drug combinations is necessary (Cohen
et al., 2008).
Predicting cellular responses to combinatorial perturbations
from responses to the individual perturbations is one of the
key conceptual goals of systems biology (Molinelli et al.,
2013). In Escherichia coli, gene expression responses to
combinations of two antibiotics, measured using fluorescent re-
porters for 100 genes, can be predicted by a linear or
nonlinear interpolation of the responses to the individual drugs
(Bollenbach and Kishony, 2011). Another study showed that
even the temporal response of 100 promoters in E. coli to all
possible combinations of four growth conditions could be
predicted by linear superposition of temporal responses to indi-
vidual conditions (Rothschild et al., 2014). Prediction of tempo-
ral expression dynamics during combination drug treatment
from responses to individual drugs was also possible for 15 pro-
teins in a human cancer cell line (Geva-Zatorsky et al., 2010).
However, it is unclear if such simple interpolation or super-
position principles for gene regulation in multidrug environ-
ments hold genome-wide and more generally across different
prokaryotes and eukaryotes.
Quantitative measurements of gene expression changes in
response to drugs are complicated by the fact that the growth
rate change caused by the drugs alone can drastically affect
gene expression (Brauer et al., 2008; Knijnenburg et al., 2009;
Metzl-Raz et al., 2017; Regenberg et al., 2006), thus obfuscating
any specific responses to the drugs. In a two-dimensional con-
centration gradient of two drugs, growth rate related changes
alone can account for as much as three-quarters of the variance
in gene expression (Bollenbach and Kishony, 2011). Further,
analysis of yeast gene deletion mutants revealed that the most
prominent geneexpression changecausedby thegenetic pertur-
bations was a general environmental-stress-response like signa-
ture associated with slower growth (O’Duibhir et al., 2014). Such
non-specific effects due to growth rate changes are an underes-
timated challenge for the interpretation of gene expression mea-
surements aiming to predict drug mechanisms and interactions.anuary 22, 2020 ª 2019 The Author(s). Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Automated Re-inoculation Protocol Allows for Steady-State Yeast Culture under Drug Combinations with Controlled Growth Rate
and Cell Density
(A) Schematic diagrams of drug interactions based on Loewe additivity (Loewe, 1928). Lines show isoboles, i.e., lines of constant growth rate. Synergy,
antagonism, and suppression are defined by the shape of the isoboles in comparison to the additive reference (left). To quantify gene expression changes due to
drug combinations, gene expression measurements in no drug, the two individual drugs, and the drug combination should be performed (circles).
(B) Schematic illustration of the experimental strategy for isogrowth profiling. Gene expression is measured along a selected growth isobole at different ratios of
the two drugs (circles, varying hue denotes varying ratio) to control for growth-rate-induced gene expression changes.
(C) Schematic illustration of how an automated system was used to produce a 243 24 discretized two-drug concentration gradient distributed over six 96-well
microplates, to inoculate S. cerevisiae, and measure growth by optical density at 600 nm (OD600).
(D) Growth measurements (OD600 over time) of yeast cells growing in a 2D-drug gradient of myriocin (Myr) and cycloheximide (Cyc). Drops in OD600 are the result
of automated re-dilution, the dotted line denotes target OD600 directly after re-dilution. Shaded areas show regions used to determine the growth rates.
(E) Growth ratesmeasured for themyriocin-cycloheximide 243 24 gradient after each of the three re-dilution steps. Green rectangles denote wells used to collect
samples for RNA sequencing at the end of incubation. See Figure S1 for the growth rates and OD600 of the collected samples.
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in drug combinations, which disentangle specific effects from
growth-rate-induced changes, reveal emergent cellular re-
sponses to drug combinations, which in turn enable faithful
predictions of three-way drug antagonism. To quantify gene2 Cell Systems 10, 1–11, January 22, 2020expression changes in drug combinations independently of
growth rate changes, we introduce a new methodology, iso-
growth profiling, which is based on measurements at constant
growth inhibition achieved by varying ratios of two drugs. Using
this technique, we found that upregulation of cytoplasmic
Table 1. Information about Drugs Used in This Study
Drug Abbr.
IC50
[mg/ml] Mechanism of Action
Cycloheximide Cyc 0.065 Inhibitor of cytosolic translation
by binding to the large ribosomal
subunit (Schneider-Poetsch
et al., 2010)
Lithium
Chloride
LiC 123103 Pleiotropic; inhibits glycogen
synthase kinase (O’Brien and
Klein, 2009), Xrn1p endonuclease
(Dichtl et al., 1997),
phosphoglucomutase
(Masuda et al., 2001), inositol
monophosphatase (Lopez et al.,
1999), protein degradation
through the proteasome (Rice
and Sartorelli, 2001), and other
enzymes (Phiel and Klein, 2001)
Myriocin Myr 0.50 Inhibitor of sphingolipid synthesis
(Miyake et al., 1995), exacerbates
the consequences of protein
misfolding (Lee et al., 2011)
Rapamycin Rap 6.83103 Inhibitor of nutrient-sensing TOR
signaling (Crespo and Hall, 2002)
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protected cells against the addition of the translation inhibitor
cycloheximide; analogously, the upregulation of DNA integrity
checkpoint by the combination of cycloheximide and myriocin
protected cells against a DNA damaging agent. Thus, emergent
regulatory responses to drug combinations enabled predicting
higher-order drug interactions. We propose a readily applicable
way of extending such growth-rate-controlled gene expression
measurements to larger sets of drug combinations.
RESULTS
Automated Re-dilution Setup Enables Yeast Culture at
Fixed Growth Inhibition by Two Drugs
We developed an automated method that precisely controls
growth inhibition for microbial cultures growing in the presence
of two drugs. This effort is necessary to keep gene expression
measurements in the presence of different drugs comparable.
It is challenging to keep growth inhibition constant both in indi-
vidual drugs and drug combinations since the drug concentra-
tions need to be quantitatively tuned according to the interac-
tions of the specific drugs. We addressed this issue by
culturing yeast populations in a fine-resolution 24 3 24 discre-
tized concentration gradient of two drugs, i.e., 576 distinct
two-drug concentrations spread over six 96-well microtitre
plates (Figure 1C).
Given equal inoculum size, populations growing at the same
growth rate would end up at the same cell density after a given
incubation period. However, some drugs have a delayed effect
on growth, allowing for faster growth at the beginning of incu-
bation. As a result, gene expression measurements would be
done at different cell density and nutrient content in the growth
medium, which influences gene expression (Kolkman et al.,
2006; Wu et al., 2004). We equalized the cell density by couplingour method with an automated re-inoculation protocol on a
customized liquid handling robot, where all cultures are re-
diluted to a fixed target population size (optical density) every
8 h (Figure 1D, STAR Methods). Three such re-dilution cycles
are performed to ensure that populations undergo approxi-
mately eight generations at 50% growth inhibition, giving
them sufficient time to reach a well-defined steady state of
exponential growth while keeping the experimental expense
manageable (Figure 1E). At the end of this procedure, we
selected specific wells where the yeast populations grew at a
defined growth rate for transcriptome analysis. These cultures
have a narrow range of cell densities (Figure S1) and thus
approximately the same nutrient content. Thus, we essentially
sampled different drug ratios along a line of constant growth
(isobole) in a two-drug concentration space, while controlling
for cell density and nutrient content.
Isogrowth RNA-Sequencing in Drug Combinations
Reveals Both Simple Interpolated and Emergent Gene
Expression Changes
We used this re-dilution setup to measure genome-wide gene
expression changes along growth isoboles for combinations of
antifungal drugs (‘‘isogrowth profiling’’). We systematically
investigated all pairwise combinations between four antifungal
drugs. The drugs were selected such that their pairwise
combinations included clear cases of antagonism, synergy,
and additivity (Figure 1A); this selection thus enabled a sys-
tematic investigation of the utility of isogrowth profiling for
characterizing drug interactions. We included the well-charac-
terized drugs cycloheximide and rapamycin but also drugs
with pleiotropic effects or unclear physiological roles, namely
lithium chloride and myriocin (Table 1). Among the strongest
drug interactions we observed are suppression of myriocin
by lithium chloride and synergy between rapamycin and myrio-
cin (Figure 2A); of note, the latter combination also has a syner-
gistic effect with respect to aging (Huang et al., 2013, 2015). After
three incubation cycles (22 h), we extracted and sequenced
the polyA-RNA from wells with a growth rate of 50% relative
to the no-drug reference (Figure 1E). To represent gene expres-
sion changes along the growth isobole, we parameterized
the growth isobole by relative drug fraction (Figure 2B; STAR
Methods). This representation has the advantage that the varia-
tion in contour length of the growth isobole due to drug inter-
action does not influence the visualization of the data.
Initial examination of gene expression changes along the
growth isoboles revealed that genes often exhibit interpolating
behavior in the drug combination, i.e., the gene expression
level in the presence of both drugs at varying ratios was between
the levels in each of the two drugs alone (Figure 2C left). An
example of this behavior is given by LEU4, which codes for an
enzyme that catalyzes the first step in leucine biosynthesis
and is upregulated by rapamycin, which signals the presence
of the nutrient-poor environment. Beyond simple interpolation,
we detected genes that show emergent responses to the drug
combination, i.e., their expression level in the combination is
more extreme than in either drug alone (Figure 2C right).
An example of this behavior are the COS2 and COS3 genes
required for vesicular sorting and degradation of membrane
proteins; these genes are upregulated in the combination onlyCell Systems 10, 1–11, January 22, 2020 3
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Figure 2. Selected Genes Responding to Pairwise Combinations of Interacting Antifungal Drugs Manifest Interpolating or Emergent
Behavior
(A) Growth response surfaces for all pairwise combinations of four drugs (myriocin, rapamycin, lithium chloride, and cycloheximide). Growth rates weremeasured
during the third iteration of the protocol shown in Figure 1. Black lines are isoboles; red line shows 50% growth inhibition isobole, gray dots indicate concen-
trations at which growth rate wasmeasured, green dots indicate wells used for sample collection for RNA sequencing. Measured values are reported in Table S4.
(B) Schematic illustration of the definition of relative drug fraction q used to reduce the dimensionality of the drug concentration space for visualizing gene
expression changes along an isobole. The relative drug fraction is equivalent to the contour length of a projection of the points along the isobole onto the
theoretical line of additivity (STAR Methods).
(C) Examples of gene expression changes along the 50% growth isobole for selected genes showing interpolating (left) and emergent (right) behavior in response
to the rapamycin-myriocin combination. Gene expression is normalized to the no-drug control.
Please cite this article in press as: Lukacisin and Bollenbach, Emergent Gene Expression Responses to Drug Combinations Predict Higher-Order Drug
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span (Huang et al., 2013, 2015). Motivated by these observa-
tions, we systematically investigated the extent of interpolating
and emergent gene expression responses in our genome-wide
datasets.
Principal Component Analysis Decomposes Responses
to Drug Combinations into Interpretable Contributions
To reveal general principles that relate responses to individual
drugs to multidrug responses, we used principal component4 Cell Systems 10, 1–11, January 22, 2020analysis (PCA), a dimensionality reduction method previously
used to disentangle gene expression changes in drug combina-
tions (Bollenbach and Kishony, 2011). This approach can reveal
structure in the data, in particular, if the responses of most
genes can be written as a linear superposition of relatively few
characteristic response modes (principal components, PCs); it
is not a priori clear though if this is possible. Using our dataset,
we calculated the PCs of the global gene expression response
along a growth rate isobole for each drug pair (STAR Methods).
This analysis revealed that between 93% and 98% of the
AB
Figure 3. Gene Expression Responses to
Drug Combinations Are a Superposition of
Consensual, Drug-Specific, and Combina-
tion-Specific Effects
(A) First (blue), second (red), and third (yellow)
principal component (PC) of genome-wide gene
expression changes along the growth isoboles for
the six drug combinations from Figure 2. PCA was
performed for each drug combination separately
(STAR Methods). Insets: pie charts showing a
fraction of variance explained by these first three
PCs.
(B) The fraction of variance explained by the first PC
versus similarity of the responses to the individual
drugs constituting the drug pair (quantified by
Pearson’s correlation coefficient) for all drug pairs in
(A). Black line shows linear regression, R2 = 0.95,
p = 93104 (t-statistic for the linear term). The first
principal component explains an increasing fraction
of the variance the more similar the effects of the
drug pairs are.
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on the specific drug pair (Figure 3A). Notably, these first three
PCs are similar across drug pairs, suggesting that each of these
PCs has a common, potentially biologically meaningful origin.
For all drug pairs, the first PC was flat (blue lines in Figure 3A)
and thus captures changes in gene expression relative to the
no-drug reference that are independent of the drug ratio along
the growth isobole. As this behavior is independent of the
inhibiting drug, it reflects the global gene expression response
to growth inhibition. The fact that the growth-rate-related first
PC explains a considerable fraction of the gene expression vari-
ance under drug combinations further validates our experi-
mental approach aimed at eliminating non-specific growth-
rate effects. When the specific gene expression responses to
the individual drugs are strongly correlated, the first PC addi-
tionally includes the common gene expression signatures of
both drugs (Figure 3B).
The second PC captured how different gene expression re-
sponses to the individual drugs are typically interpolated (red
lines in Figure 3A). Genes often respond differently to different
drugs, which inevitably leads to conflicting responses in the
presence of both drugs. The second PC exposes the default
way in which genes that exhibit no specific response to the
drug combination resolve such conflicts. The shape of the sec-
ond PC was approximately linear, but sometimes clearly
sigmoidal, in particular for the strongly antagonistic drug pair
cycloheximide-rapamycin (Figure 3A). This result aboutgenome-wide transcriptional regulation in
a eukaryotic model system generalizes
previous observations from bacteria that
antagonistic drug interactions coincide
with a sigmoidal interpolation (‘‘prioritiza-
tion’’) of gene expression conflicts, while
additive combinations lead to a more
linear interpolation (‘‘averaging’’) (Bollen-
bach and Kishony, 2011). The large frac-
tion of variance explained by the first two
PCs implies that, for most yeast genes,the response to drug combinations is largely predictable from
their responses to the individual drugs alone.
Our genome-wide dataset further enabled us to systematically
identify emergent behaviors, where the expression of a gene un-
der a drug combination is higher or lower than under either drug
alone. For all drug pairs, such emergent responses were
captured by the third PC (yellow lines in Figure 3A). Genes with
a strong third PC are specifically up- or downregulated in the
presence of both drugs due to effects that are absent in either
drug alone. Based on the observed shapes of the PCs, we hy-
pothesized that functional analysis of genes governed strongly
by the second and third principal component should yield test-
able predictions about the specific effects of individual drugs
and drug interactions on cell physiology, respectively.
Analysis of Specific Drug Effects Reveals that Myriocin
Prepares Yeast for Respiratory Medium
We first exploited our dataset to extract the specific effects of
individual drug perturbations on cell physiology. Because of
the confounding effects of growth inhibition, this cannot be
achieved by simple comparisons of gene expression measure-
ments in the presence and absence of a drug alone. This prob-
lem is particularly evident for the abundances of ribosomes
and mitochondria, which are strongly affected by growth rate
(Metzl-Raz et al., 2017). Therefore, we leveraged the fact that,
by construction, the second PC is orthogonal to the first PC,
which captures the non-specific growth rate effect. The secondCell Systems 10, 1–11, January 22, 2020 5
Figure 4. Functional Analysis of Genes with Interpolating Behavior Reveals Specific Effects of Individual Drugs on Cell Physiology
(A) Cumulative distributions of mean relative second PC scores for individual genes across experiments for the respective drug (STAR Methods). Before
averaging, the scores were inverted if needed, such that positive scores always indicate upregulation in the given drug. Cellular functions that are enriched based
on gene ontology (GO) analysis of up- and downregulated genes are highlighted in green and red, respectively. Themost significant GO term that has no offspring
(more specific) term with p% 109 is displayed (STAR Methods). For cycloheximide, no functional group was found to be enriched for downregulation at the
chosen level of significance. See also Table S1.
(B) Schematics of hypothetical growth curves during diauxic shifts from fermentation to respiration: the diauxic lag (left) should be shortened if the mitochondrial
translation is induced while still in fermentative medium (right).
(C) Growth curves of yeast cultured in YPG glycerol medium inoculated from glucose overnight culture at different concentrations of myriocin (left) and cyclo-
heximide (right). Intermediate myriocin concentrations drastically shorten the diauxic lag time; in contrast, the control drug cycloheximide has no effect on diauxic
lag. MIC = Minimum Inhibitory Concentration, 2.5 mg/ml for myriocin, 0.16 mg/ml for cycloheximide.
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drug responses, can be used to rigorously identify specific
responses of genes to individual drugs. To this end, we quanti-
fied the fraction of variance in expression along the two-drug iso-
bole that is explained by the second PC for each gene. To iden-
tify the gene expression change that can be specifically
attributed to a given drug, we averaged this fraction across all
experiments involving that drug, accounting for the sign of the
expression change (STAR Methods). This procedure does not
necessarily average out the entire contribution of the other
drugs and, due to inherent limitations of PCA, it might not cap-
ture more complex behaviors of smaller gene groups. Neverthe-
less, it estimates the specific effect of a single drug on gene
expression more thoroughly than a simple comparison to a sin-
gle reference condition. We then sorted the genes according
to this average and performed gene ontology enrichment anal-
ysis (STAR Methods). This procedure produces a list of func-
tional gene groups that are specifically up- or downregulated
in response to each drug in a way that is not obfuscated by
growth rate changes or any other non-specific effects of drugs.
The most strongly enriched up- and downregulated functional
gene groups in the cellular response to individual drugs
confirmed expectations in the light of published literature (Fig-
ure 4A; Tables 1 and S1). Cycloheximide, a drug that binds to6 Cell Systems 10, 1–11, January 22, 2020the large ribosomal subunit (Schneider-Poetsch et al., 2010)
and is commonly used to inhibit cytosolic translation, elicited
upregulation of genes involved in cytoplasmic translation (Fig-
ure 4A). Rapamycin, a specific inhibitor of nutrient-sensing
TOR signaling (Crespo and Hall, 2002), triggered a decrease
in ribosome biogenesis and an increase in amino acid biosyn-
thesis (Figure 4A)—canonical responses to low-nutrient environ-
ments (Mayer and Grummt, 2006; Peng et al., 2002). The pleio-
tropic drug lithium chloride led to upregulation of proteasome
assembly with a concomitant decrease in amino acid biosyn-
thesis (Figure 4A). Both observations are consistent with a
cellular response to the inhibition of protein degradation—a
plausible effect as lithium chloride is known to inhibit protein
degradation through the proteasome (Rice and Sartorelli, 2001)
along with inhibition of other enzymes (Table 1). Together, these
results corroborate that our analysis of the second PC can iden-
tify specific cellular responses to individual drugs and thus pro-
vide insights into drug modes of action.
Furthermore, this analysis exposed previously unreported ef-
fects of individual drugs. We found that myriocin, a known inhib-
itor of sphingolipid synthesis (Miyake et al., 1995), leads to an in-
crease in mitochondrial translation and downregulation of
protein degradation. The latter is consistent with previous re-
ports that myriocin exacerbates the consequences of protein
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mitochondrial translation was entirely unexpected. Therefore,
we performed additional experiments to test the prediction that
the upregulation of mitochondrial translation is one of the major
physiological effects of myriocin.
We reasoned that the mitochondrial ribosome primarily trans-
lates genes needed for oxidative metabolism (Couvillion et al.,
2016). Therefore, the increasedmitoribosome expression should
increase respiratory capacity, especially in conditions where this
capacity is not maximal to begin with, e.g., during fermentative
overflow metabolism in glucose. Thus, we hypothesized that
the mitoribosome overexpression triggered by myriocin treat-
ment should have a growth rate cost on a fermentative carbon
source, but should shorten the diauxic lag upon a shift to an
oxidative carbon source such as glycerol (Figure 4B). Indeed, in-
termediate concentrations of myriocin drastically shortened
this diauxic lag, while higher doses led to more pronounced inhi-
bition of fermentative growth (Figure 4C). Inhibition by a control
drug (cycloheximide) supported that the shortening of the dia-
uxic lag was not due to a non-specific decrease in growth rate,
but rather due to specific effects of myriocin, confirming the pre-
diction of our analysis based on the second PC. Overall, these
results show that abstracting growth rate effects from the spe-
cific gene expression changes triggered by individual drugs
can reveal far-reaching changes in cellular physiology and
metabolism.
Emergent Response to Drug Combinations Predicts
Antagonisms with Drugs Targeting Upregulated
Pathways
We next sought to identify the physiological consequences of
drug combinations that go qualitatively beyond those brought
about by the constituent drugs alone. We reasoned that func-
tional analysis of the genes strongly governed by the third PC
should expose the emergent effects of the two drugs on cell
physiology, even if these genes are also affected by growth
rate or by the individual drugs alone. To identify the emergent
effects of each drug combination, we sorted the genes by their
third PC score and, after accounting for the sign of the third
PC, performed gene ontology enrichment analysis (STAR
Methods). This procedure revealed functional groups (Tables
S2 and S3) that showed significant emergent upregulation (for
five drug pairs) or downregulation (for two drug pairs, Figure S2).
In particular, a DNA replication checkpoint showed an emergent
response to the myriocin-cycloheximide combination (Fig-
ure S2). Similarly, myriocin and lithium chloride together trig-
gered a specific increase in ribosome biogenesis. Our analysis
thus identified cellular functions that specifically respond to the
drug combinations.
To validate this analysis and explore its utility, we made spe-
cific testable predictions based on the identified emergent
gene regulation. We reasoned that the upregulation of functional
groups of genes in response to drug combinations may not al-
ways be adaptive. If upregulation is non-adaptive, it could create
a buffer for the cell when exposed to a third drug that inhibits
the upregulated pathway, rendering the cell less sensitive to
the third drug (Figure 5A). In other words, this would lead to
three-way drug antagonism. To test this idea, we added the
DNA damaging agent methyl methanesulfonate (MMS) on topof the myriocin-cycloheximide combination, since the myrio-
cin-cycloheximide combination on its own triggered emergent
upregulation of a DNA replication checkpoint (Figure 5B).
Indeed, the addition of this third compound inverted the syner-
gism between myriocin and cycloheximide to antagonism
(Figure 5C). Similarly, adding the translation inhibitor cyclohexi-
mide on top of the myriocin-lithium chloride combination, which
triggered an emergent increase in ribosome synthesis (Fig-
ure 5B), strongly amplified antagonism (Figure 5D). These results
suggest that emergent gene regulation in response to drug
combinations, identified upon proper accounting for non-spe-
cific effects and individual drug effects, often enables faithful
predictions of higher-order interactions with additional drugs.
Emergent Responses to Drug Combinations Should Be
Measured Where the Drug Interaction Is Strongest
While this functional analysis of the third PC is valuable for char-
acterizing the specific effects of drug combinations, this
approach is relatively hard to utilize: our gene expression mea-
surements along the two-drug growth isobole (Figures 1 and 2)
require feedback-controlled liquid handling and are not readily
scalable to larger numbers of drug pairs. Therefore, we aimed
to establish a more accessible protocol that provides compara-
ble information on emergent gene regulation under drug combi-
nations at a lower experimental effort. To identify genes strongly
governed by the third PC, it would in principle suffice to measure
gene expression in the presence of the individual drugs alone
(i.e., at both ends of the isoboles) and at one point in drug con-
centration space in the middle of the isobole, where both drugs
are present. The ideal choice for the latter would be the point in
drug combination space where the third PC has its peak, as this
point can provide maximum information about emergent gene
expression. We asked whether such a point on the isobole could
be identified without measuring the gene expression along the
entire isobole.
We observed that the peak of the third PC generally coincides
well with the point in drug space where the deviation of growth
rate from the additive expectation is most pronounced (Figures
6A and S3). In other words, the third PC is maximal at the drug
ratio where the drug interaction is strongest. This observation
exposes a simple, yet powerful principle for gaining maximum
information from a single gene expression measurement under
a drug combination: such measurements should be performed
at drug concentrations where the growth rate deviatesmaximally
from the additive expectation (Figures 6B and S4)—apoint that is
readily identified from a standard growth-rate-response surface
measurement.
DISCUSSION
Understanding the principles that govern gene expression re-
sponses to multiple drugs can facilitate the design of new com-
bination therapies. However, measurements of gene expression
responses to drugs are obfuscated by changes in growth rate
(Bollenbach and Kishony, 2011; O’Duibhir et al., 2014). We found
that at least 75% of all variations in gene expression in yeast re-
sponding to combinations of two drugs can be attributed simply
to changes in growth rate. Thus, we introduced isogrowth
profiling, a framework for measuring gene expression changesCell Systems 10, 1–11, January 22, 2020 7
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Figure 5. Cellular Functions Showing Emergent Responses to Drug Combinations Enable Predictions of Higher-Order Drug Interactions
(A) Schematic: non-adaptive upregulation of gene expression in response to the combination of two drugs (left; green shading) may protect against a third drug
targeting the upregulated pathway (middle) and thus lead to higher-order antagonism (right panel). The solid red line is the 50% growth rate isobole in each
condition, the dashed red line shows a 50% growth rate isobole in the absence of drug C for comparison.
(B) Cumulative distribution functions of relative third PC scores for individual genes for the drug combinations shown in C (top) and D (bottom). Cellular functions
that are enriched based on gene ontology (GO) analysis of upregulated genes are highlighted in green; only the most significant GO term that has no offspring
(more specific) term with p% 106 is shown (STAR Methods). For other drug pairs, see Figure S2 and Tables S2 and S3.
(C) Dose-response surfaces for the myriocin-cycloheximide combination in the absence (left) and in the presence (right) of the DNA damaging agent methyl
methanesulfonate (MMS). The interaction is modified by a third drug targeting the pathway upregulated in the two-drug combination: MMS inverts synergism
between myriocin and cycloheximide into antagonism. Growth rates are normalized to the growth rates in the absence of both myriocin and cycloheximide.
(D) Ribosomal inhibitor cycloheximide increases antagonism between myriocin and LiCl, leading to strong suppression. Yellow arrows highlight the change to
stronger antagonism. Growth rates are normalized to the growth rates in the absence of both myriocin and LiCl. Measured values are reported in Table S5.
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Figure 6. Gene Expression Responses to
Drug Combinations Yield Maximum Infor-
mation at Drug Concentrations that Deviate
Maximally from Additivity
(A) Third PC as in Figure 3A (yellow) and deviation
of growth isobole from theoretical additivity line
(green; see Figure S3 for definition) for selected
drug pairs. Green dot labels the point of maximum
deviation. For other drug pairs, see Figure S3.
(B) Schematic of detailed (left) versus simplified
(right) isogrowth profiling: in the simplified version,
the effects of single drugs are measured at the
same growth rate (red and blue circles), but only a
single measurement is performed in the presence
of both drugs, at the point in two-drug space
where the drug interaction is maximum (magenta
circle). See also Figures S4 and S5 for the justifi-
cation of the choice of measurement points.
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Interactions, Cell Systems (2019), https://doi.org/10.1016/j.cels.2019.10.004in drug combinations while keeping growth rate constant (Fig-
ure 2). Beyond growth effects, most of the gene expression vari-
ance is well approximated by interpolating the responses to the
individual drugs (Figure 3). These data corroborate the view that
regulatory responses to drug combinations are largely predict-
able from the responses to the constituent drugs, as previously
observed in prokaryotes and in human cells (Bollenbach and
Kishony, 2011; Geva-Zatorsky et al., 2010).
We found that some genes show emergent responses to
drug combinations. Even though these genes contribute little
to global gene expression variance, they are likely responsible
for key phenomena caused by drug combinations that are
otherwise hard to rationalize. Identifying cellular functions
that show emergent responses enabled us to predict antago-
nisms with a third drug (Figure 5). Our growth-rate-controlled
experiment enabled abstracting both growth-rate-dependent
and drug-specific gene expression changes from emergent
drug-combination-specific changes even for highly growth-
rate-dependent genes, such as ribosomal genes. In this way,
we discovered emergent responses that would otherwise be
masked by strong growth-rate-dependent effects (Figure S5).
In particular, the combination of myriocin and cycloheximide
caused upregulation of a DNA replication checkpoint, protect-
ing the cells from a DNA damaging agent as predicted; simi-
larly, the combination of lithium chloride and myriocin upregu-
lated cytoplasmic ribosomes and protected cells from a
translation inhibitor (Figure 5). We identified various other
emergent responses (Tables S2 and S3). In many cases, the
higher-order antagonisms predicted based on these observa-
tions cannot be easily tested because drugs targeting the up-
regulated pathway are unavailable. For example, the func-
tional consequences of upregulating vesicular trafficking in
the combination of myriocin and rapamycin would have to
be tested by other assays. Our results suggest that emergent
gene regulation under drug pairs often singles out cellular
functions at the heart of higher-order drug interactions.Recent work suggested that growth
rates in higher-order drug cocktails may
be largely predictable from the pairwise
interactions between the constituentdrugs (Wood et al., 2012; Zimmer et al., 2016, 2017). However,
true higher-order drug interactions also seem common (Tekin
et al., 2018). Our results indicate that emergent gene expression
responses to pairwise drug interactions enable predictions of
such higher-order interactions. Why is that so? Yeast evolved
to respond to stresses it frequently encounters in its natural
environment. During the course of evolution, stress caused by
drugs targeting specific parts of the cellularmachinery was prob-
ably rare compared to changes in nutrient availability, tempera-
ture, pH, etc. Thus, yeast may not have adaptive responses to all
specific stresses caused by drugs, and this seems even less
likely for combinatorial stressors. Hence, drug combinations
likely trigger non-adaptive gene expression changes, which do
not increase fitness. In other words, the emergent regulation
of specific pathways under drug combinations is likely caused
indirectly by a regulatory machinery that evolved for other pur-
poses (Price et al., 2013). The non-adaptive emergent upregula-
tion of a cellular pathway in response to a drug pair can create a
‘‘buffer’’ against the action of a third drug that inhibits the upre-
gulated pathway, or, conversely, a susceptibility for a drug that
requires the upregulated pathway for its action.
Isogrowth profiling can identify detailed effects of individual
drugs and drug combinations on cell physiology, which can
be used to predict certain three-way drug interactions. While
we focused on a single model organism and a limited number
of drugs, we anticipate that the basic principles uncovered
here are more broadly applicable to other systems and drugs.
However, isogrowth profiling requires a large number of gene
expression measurements. To increase its applicability, we pro-
pose a simplified version that requires measuring gene expres-
sion at only four well-chosen points in two-dimensional drug
concentration space, where the drug interaction is maximal
while the overall inhibitory effect is kept constant (Figure 6).
This simplified framework provides almost complete information
on emergent gene regulation (Figure S4) and facilitates system-
atic investigations of gene expression responses for all pairwiseCell Systems 10, 1–11, January 22, 2020 9
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principle, not be limited to drugs that inhibit growth but extend-
able to inhibitors of any cellular function as long as the inhibitory
effect can be quantified. A large-scale characterization of the
emergent physiological changes under drug combinations
using the approach introduced here has the potential to inform
predictive algorithms for the design of advanced multidrug
therapies.
Key Changes Prompted by Reviewers Comments
In response to reviewers comments, the discussion was slightly
modified to better reflect that the current study is limited to a sin-
gle model organism and a few drugs. Further, an explicit mention
of the limitations of PCA with respect to discovering responses
caused by a small number of genes was added. A more detailed
explanation of the evolutionary argument that responses to
combinatorial drug perturbations are likely non-adaptive was
also included. For context, the complete Transparent Peer Re-
view Record is included within the Supplemental Information.
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Chemicals, Peptides, and Recombinant Proteins
Lithium chloride Sigma Aldrich L9650
Cycloheximide Sigma Aldrich 37094
Myriocin Sigma Aldrich M1177
Rapamycin Sigma Aldrich 37094
Yeast extract Sigma Aldrich Y1625
Peptone Sigma Aldrich 91249
Dextrose Sigma Aldrich D9434
Methyl methanesulfonate Sigma Aldrich 129925
Glycerol Sigma Aldrich G5516
Critical Commercial Assays
RiboPure RNA Purification Kit for yeast Thermo Scientific AM1926
NEBNext Magnesium RNA Fragmentation Module New England Biolabs E6150S
Dynabeads oligo-dT kit Invitrogen 61012
Agencourt AMPure XP Beckman Coulter A63881
Quick Ligation Kit New England Biolabs M2200S
KAPAHiFi Hot-Start ReadyMix VWR 733-2430
RNase H New England Biolabs M0297S
Deposited Data
RNA sequencing data GEO GSE138256
Experimental Models: Organisms/Strains
Saccharomyces cerevisiae BY4741 EuroScarf Y00000
Software and Algorithms
Matlab Mathworks
TopHat Kim et al., 2013
UMI-tools Smith et al., 2017
featureCounts Liao et al., 2014
Gorilla Eden et al., 2009LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Tobias Bollenbach
(t.bollenbach@uni-koeln.de). This study did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Saccharomyces cerevisiae strain BY4741 was obtained from EuroScarf repository, cat. No. Y00000.
METHOD DETAILS
Automated Re-inoculation Setup for Reproducible Yeast Culture
Saccharomyces cerevisiae strain BY4741 was grown in 20 ml of YPD broth - yeast extract (Sigma Aldrich cat. No. Y1625), peptone
(Sigma Aldrich cat. No. 91249), dextrose (Sigma Aldrich cat. No. D9434) in a 100 ml conical flask shaken 220 rpm at 30C overnight
and then distributed into a 96-well plate (non-treated transparent flat bottom, Nunc). A customized liquid handling robot (Tecan
Freedom Evo 150) with 8 liquid handling channels and a robotic manipulator was used to produce a two-dimensional discretised
two drug 24 3 24-well gradient in YPD spread over six 96-well plates and to inoculate the yeast overnight culture to final opticale1 Cell Systems 10, 1–11.e1–e3, January 22, 2020
Please cite this article in press as: Lukacisin and Bollenbach, Emergent Gene Expression Responses to Drug Combinations Predict Higher-Order Drug
Interactions, Cell Systems (2019), https://doi.org/10.1016/j.cels.2019.10.004density at 600 nm (OD600) of 0.15 and final liquid volume in thewell of 200 ml. The discretized drug gradient was set up as in Chevereau
and Bollenbach (2015), that is the concentration of each drug was spaced according to c = cmaxðx3 + axÞ=ð1 + aÞ, where cmax was
the highest concentration used, x was linearly spaced from 0 to 22 steps (with replicate for no drug condition) and a = 1=3. Working
drug solutions were prepared either by adding the respective amounts of concentrated DMSO drug stocks thawed from20C stor-
age (no refreezing) previously prepared from stock chemicals (cycloheximide cat. No. 37094, myriocin cat. No. M1177, rapamycin
cat. No. 37094, all from Sigma Aldrich), or by dissolving directly in YPD and sterile-filtering (LiCl, cat. No. L9650 Sigma Aldrich).
The six plates were incubated for three iterations, each lasting 8 h. Each iteration consisted of incubation and a re-inoculation.
Plates were incubated in an automated incubator (Liconic Storex) kept at 30C, >95% humidity, vigorously shaken at >1,000 rpm.
During the incubation, OD600 was measured every 15 min in a Tecan Infinite F500 plate reader. In addition to shaking during incu-
bation, directly before each measurement, plates were shaken on a magnetic shaker (Teleshake; Thermo Scientific) at 1,100 rpm for
20 s. During re-inoculation, a volume Vi of yeast culture specifically calculated for each well so as to achieve OD600=0.15 after dilution
(while 1.5 ml% Vi%100 ml) was added to a fresh medium in a new 96-well plate containing a drug cocktail pipetted in such a way that
the final concentration of both drugs, when accounted for the size of the inoculum, was the same as before the re-inoculation step,
and the total volume of liquid in the well was 200 ml. During the re-inoculation the plate to be re-inoculated was not shaken for a max.
of 15 mins. The entire setup was kept in a climate room at 30C and 50% humidity. The growth rate for each well for each iteration
was quantified from the OD600 increase over time by a linear fit of log2(OD600) for the last 10 measurements (2.5 h) before re-inoc-
ulation. All growth rates were normalized to the growth rate of the parent strain in the absence of any drugs measured on the
same day.
RNA Extraction and Sequencing
For RNA extraction, wells growing at a relative growth rate close to 50% at the end of the third iteration of the automated re-inocu-
lation culture were selected. RNA extraction was performed using the RiboPure RNA Purification Kit for yeast (Thermo Scientific, cat.
No. AM1926). The purity of extracted RNAwas confirmed for selected samples using the Agilent RNA 6000Nano Bioanalyzer Kit. The
library was prepared as in (Bar-Ziv et al., 2016). In brief, the purified RNA was fragmented using the NEBNext Magnesium RNA
Fragmentation Module (New England Biolabs cat. No. E6150S), poly(A)-selected using Dynabeads oligo-dT kit (Invitrogen, cat.
No. 61012) and reverse-transcribed to cDNA using custom poly(T) primers barcoded for multiplexing as well as containing 4-nt-
long unique molecular identifier. The resulting complementary DNA strands were pooled and purified [RNase H (NEB cat. No.
M0297S), Agencourt AMPure XP (Beckman Coulter cat. No. A63881)], a custom double-stranded adapter ligated to the 30 end using
Quick Ligation Kit (NEB cat. No. M2200S), second cDNA strand synthesized with KAPAHiFi Hot-Start ReadyMix (VWR cat. No. 733–
2430), amplified and 50 bp single-end sequenced on Illumina HiSeq 2500 using a primer complementary to the adaptor at the end
opposite to the poly(A).
Diauxic Shift Measurements
S. cerevisiae strain BY4741 was grown in YPD broth overnight and diluted100-fold into YPGmedium [yeast extract (Sigma Aldrich
cat. No. Y1625), peptone (Sigma Aldrich cat. No. 91249), glycerol (Sigma Aldrich cat. No. G5516), final glycerol conc. 3% v/v] con-
taining varying amounts of myriocin or cycloheximide. The antifungal drugs were arranged in an exponential gradient created by 2-
fold serial dilution. The cultures were incubated in a 96-well microplate in total volume of 200 ml, in an automated incubator (Liconic
Storex) kept at 30C, > 95% humidity, vigorously shaken at >1,000 rpm; OD600 was measured every30 min in a Tecan Infinite F500
plate reader. In addition to shaking during incubation, directly before each measurement, plates were shaken on a magnetic shaker
(Teleshake; Thermo Scientific) at 1,100 rpm for 20 s.
Three-Drug Interaction Measurements
For three-drug interaction assays, S. cerevisiae strain BY4741 was diluted into YPDmedium (53103-fold final dilution) from a thawed
overnight culture kept at 80C with 15% glycerol. An 83 83 8 discretized gradient of the respective drugs was prepared by serial
dilution and distributed across eight 96-well plates. The plates were sealed with Parafilm M and shaken at1,000 rpm on a Titramax
1000 shaker in a 30C incubator overnight. The next day, measurements were performed manually approximately every hour in a
Biotek Synergy H1 microplate reader. The plates were re-sealed with Parafilm after each measurement, and incubation was
continued as before. Growth rates for each well were quantified from the OD600 increase over time by a fit to the linear section of
log2(OD600) in the range 0.01% OD600% 3.
QUANTIFICATION AND STATISTICAL ANALYSIS
The reads resulting from sequencing were demultiplexed, aligned to annotated reference S. cerevisiae genome R64-2 using TopHat
(Kim et al., 2013), deduplicated using UMI-tools (Smith et al., 2017) and quantified using featureCounts (Liao et al., 2014). Gene
expression changes were further analyzed using custom written MATLAB scripts. Briefly, to account for sample-to-sample variation
and low molecule noise, quantile normalization was applied using the quantilenorm function over the entire dataset, and the most
highly expressed two-thirds of the genes were used for further analysis. Principal component (PC) analysis was performed forCell Systems 10, 1–11.e1–e3, January 22, 2020 e2
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expression in YPD medium containing no drug, median-filtered along the growth isobole. Results along the growth isobole were
visualized using the relative drug fraction qA =
cA
ICA50
=
 
cA
ICA50
+
cB
ICB50
!
. Gene ontology enrichment analysis for genes up- or down-regu-
lated and strongly governed by the third PC was performed by sorting the genes by their relative third PC loading in descending or
ascending order, respectively, and looking for Gene Ontology (GO) terms enriched in the upper part of the list (all possible partitions)
using GOrilla (Eden et al., 2009). The relative third PC loading for each gene was calculated by dividing the third PC loading for that
gene by the Euclidean norm of the vector containing loadings for all the principal components for that gene. GO terms associatedwith
retrotransposon activity were disregarded in the analysis. Gene enrichment analysis for genes up- or down-regulated and strongly
governed by the second PCwas performed analogously, except for each drug the relative second PC loadingswere averaged across
experiments containing the respective drug. Before averaging, the sign of the second PC coefficients and loadings was inverted for
experiments where the respective drug is shown on the left side of the x-axis in Figure 3A, so as to ensure consistency in keeping the
relative second PC positive if the gene was upregulated in that drug.
DATA AND CODE AVAILABILITY
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